Medical Cannabis in the United Kingdom
In 2018 medical cannabis products were legalised for the first time in the United Kingdom. Subsequent to this legalisation, the country’s medical cannabis market is forecasted to increase in size massively. In 2019, the revenue of the medicinal cannabis market in the UK was less than 200 thousand U.S. dollars, by 2024 this revenue is expected to be approximately 1.3 billion U.S dollars.
The number of patients using medical cannabis products is predicted to increase significantly. At the end of 2019, there were less than 250 active medical cannabis users, by 2024 the number of users is expected to rise to approximately 337.9 thousand.
Across all age groups in Great Britain the majority of respondents to a survey would consider to some extent using cannabis-based medical products if there was strong evidence it would be an effective treatment for their health condition. Although, it is the older age groups who would be slightly more open to using medical cannabis for their health conditions, with 48 percent of those aged over 65 years saying they would definitely consider using these products and 30 percent saying they would probably consider it.
In 2019, 45 percent of British adults said they strongly supported the legalisation of some cannabis-based medicines by the British government which allows specialist medical practitioners to prescribe these medicines to patients, while a further 32 percent support this to an extent. There is very little opposition to the legalisation of medical cannabis among the British population with only four percent of respondents opposing to any extent.
FLWR: The Rize Medical Cannabis and Life Sciences UCITS ETF seeks to track the Foxberry Medical Cannabis & Life Sciences Index. The objective of the Index is to provide exposure to companies involved in the global medical cannabis and cannabis-related life sciences sectors, with a focus on companies in the biotechnology/pharma and hemp and cannabidiol (CBD) sectors. The Index excludes companies that are considered to be either non-compliant with state and federal laws in the countries in which they operate and/or directly involved in the production and/or distribution of cannabis and/or cannabis-derived products containing more than hemp-defined levels of tetrahydrocannabinol (THC) for the recreational consumer market.
Capital at Risk Warning: An investment in the Fund(s) involves risks, including illiquidity, lack of dividends, loss of investment and dilution, and it should be done only as part of a diversified portfolio. The Funds may be registered or otherwise approved for distribution to the public in one or more European jurisdictions. Investors should continue to consider the terms of investment in any Fund (or Share Class thereof) carefully and seek professional investment advice before taking any decision to invest in such Fund (or Share Class thereof).